Shikha Singla, MD

Assistant professor of rheumatology @medicalcollege, kathak dancer and a mom.

[Shikha Singla, MD @docrheumatic]

@somedocs Best part of being a #rheumatologist is dealing with a complex interplay of therapeutic (acute and chronic) interventions, risk management, and lifestyle modifications. And developing lifelong relationships with our patients. #SoMeDocs #Rheumatology

[NatRevRheumatol @NatRevRheumatol]

New content online: Consensus definitions of complex-to-manage and treatment-refractory psoriatic arthritis: a GRAPPA initiative https://t.co/fU38csuS7P

[HCPLive @HCPLiveNews]

We're here on-site at #SDPA2025 @dermPA in San Antonio, TX!🤠

Our team interviewed @docrheumatic of @MedicalCollege regarding her session on the overlap between #psoriasis and #PsoriaticArthritis. Want to learn more?

View: https://t.co/3oQsv3CEqd

[Shikha Singla, MD @docrheumatic]

@Abhishek_joints Thank you!

[Shikha Singla, MD @docrheumatic]

Biologic Sequence for the Treatment of Psoriatic Arthritis Following Nonresponse: A Narrative Review | Dermatology and Therapy https://t.co/UC22OxFmkO

[JCR: Journal of Clinical Rheumatology @JRheumatology]

🌍 How do global guidelines tackle PsA?
New review compares ACR, EULAR, BSR, GRAPPA & PANLAR:

📌 All agree: Treat-to-target
🔄 Differences in:
• Biologic/tsDMARD sequencing
• Enthesitis & dactylitis management
• Comorbidity integration

🔍 Read&RT
https://t.co/QcqH9jGrd8

[GRAPPA Network - Official @GrappaO]

🎙️ New Inside GRAPPA Episode!

Defining Difficult-to-Treat and Complex-to-Manage Psoriatic Arthritis

What truly makes a PsA case difficult to treat or complex to manage? In this compelling episode, host Dr. Hanna Johnsson dives into this crucial question with GRAPPA experts:

🔹 Dr. Fabian Proft (Charité Berlin)
🔹 Dr. Shikha Singla (Medical College of Wisconsin)

Tune in to hear their insights and how GRAPPA is working to define and improve care for these challenging cases.

🎧 Don’t miss it—listen now wherever you get your podcasts or here:
https://t.co/FNHRE0XBFa

#InsideGRAPPA #PsoriaticArthritis #Rheumatology #GRAPPA #PsA #psoriaticdisease

@HannaJohnsson3 @ProftDr

[Shikha Singla, MD @docrheumatic]

Secular trends in biologic prescribing for psoriasis and psoriatic arthritis, 2014‐2024 - Mirza - Arthritis & Rheumatology - Wiley Online Library ⁦@rheum_cat⁩ ⁦@EBRheum⁩ https://t.co/QqTMKDFmBp

[André Ribeiro @Dr_AndreRibeiro]

⚠️ What makes PsA difficult to treat?

Our new GRAPPA-led study asked 570 patients in 10 languages 🌍

🗣️ Findings? Fatigue, persistent pain, and life impact go far beyond what labs can show.

🔗 https://t.co/uDvu15VJai

#D2T #PsA
@GrappaO
@ProftDr

[Shikha Singla, MD @docrheumatic]

Higher Rates of Psoriatic Arthritis in Patients with Calcium Pyrophosphate Deposition Disease than in Controls: A Retrospective Cohort Study https://t.co/3M6sE8dH2g

[Shikha Singla, MD @docrheumatic]

@Anjum12Siddiqui @darpan06T @Abhishek_joints @dr_immuno29 @KishanMajithiy5 @AbilashKrishn90 @Rajatku24760827 It was so refreshing and stimulating to hear all of your perspectives. Thanks again for this opportunity. Good luck for your future endeavors!

[Abhishek G P @Abhishek_joints]

Had d privilege of hosting Dr. Shikha Singla from University of Wisconsin & Director of PsA program! She delivered an insightful lecture on "Difficult to treat PsA," engaging with residents & offering invaluable opinions on our cases.A truly enriching experience!

[Shikha Singla, MD @docrheumatic]

@Abhishek_joints @dr_immuno29 @DrNishant_GMC @ankushpm101 It was truly an honor to present at KGMC. I was humbled to learn about the challenges faced by my colleagues in my home country regarding management of psoriatic arthritis.

[International Psoriasis Council @IpcPs]

The #IPC symposium at #AAD2025, Preventing Comorbid Disease in Psoriasis, is today at 2:00 PM EST in Orange County Convention Center, Room W204ABC, Level 2, West Concourse. Thank you to @AbbVie for supporting this symposium!

https://t.co/AclhHjv0LY

#IPCEvent #IPCSymposium

[GRAPPA Network - Official @GrappaO]

📢 Live from the SPARTAN-GRAPPA-ASAS Educational Symposium at #ACR2024!

Dr. Shikha Singla shared key insights on how biological sex influences the response to advanced therapies in PsA, with effects varying by drug class.

Key takeaways:
✔️ Sex differences matter in treatment outcomes.
✔️ Limitations: Selective reporting.
✔️ Future trials should report baseline characteristics and endpoint results by sex.

Groundbreaking discussions shaping the future of PsA care!

#PsoriaticArthritis #Rheumatology #grappanetwork

[GRAPPA Network - Official @GrappaO]

Don't forget to register for the the upcoming SPARTAN-GRAPPA-ASAS Symposium next month!

This event is open for registration now and promises to be an incredible opportunity to explore research and insights on spondyloarthritis and psoriatic disease. Don’t miss out—secure your spot today and join us for this much anticipated event! 📷 Register here: https://t.co/tSZ80nATIj

#psoriaticdisease #spondyloarthritis #rheumatology

@Official_ASAS @SPARTAN_Updates

[Shikha Singla, MD @docrheumatic]

MACE Risk Similar Across Biologic Classes Used to Treat Psoriasis, Psoriatic Arthritis https://t.co/kANg5kxy9g https://t.co/kANg5kxy9g
@EBRheum @rheum_cat

[Shikha Singla, MD @docrheumatic]

Sequencing of Targeted Therapy in Psoriasis: Does it Matter? | American Journal of Clinical Dermatology https://t.co/Ok9qX7Vxoi

[Shikha Singla, MD @docrheumatic]

Ongoing efforts aim to differentiate biologically refractory cases from cases with comorbid conditions and social factors that can contribute to treatment nonre…

Source: Medscape https://t.co/ZPu6rZ0oCj

[Shikha Singla, MD @docrheumatic]

Paradoxical psoriasis with IL-17 inhibitors https://t.co/JjpF5loF5S @DimitriLuiz1

[André Ribeiro @Dr_AndreRibeiro]

📢 PsA is a complex disorder where only 23.1% of PsA patients achieve remission. Factors like disease activity, comorbidities, and treatment accessibility contribute. So, we need to better understand D2T-PsA. New publication by the GRAPPA project of D2T/C2M-PsA

🧵
🔗👇